Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PD-1 anticorps

Cet anticorps Rat Monoclonal détecte spécifiquement PD-1 dans FACS et Func. Il présente une réactivité envers Souris.
N° du produit ABIN6253466

Aperçu rapide pour PD-1 anticorps (ABIN6253466)

Antigène

Voir toutes PD-1 (PDCD1) Anticorps
PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivité

  • 191
  • 108
  • 28
  • 5
  • 4
  • 3
Souris

Hôte

  • 102
  • 96
  • 56
  • 13
  • 4
  • 3
  • 2
  • 2
  • 1
  • 1
Rat

Clonalité

  • 207
  • 67
  • 5
Monoclonal

Conjugué

  • 132
  • 19
  • 15
  • 14
  • 8
  • 6
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 4
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp PD-1 est non-conjugé

Application

  • 170
  • 83
  • 81
  • 53
  • 44
  • 21
  • 19
  • 19
  • 18
  • 16
  • 13
  • 13
  • 13
  • 10
  • 10
  • 6
  • 5
  • 4
  • 4
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), Functional Studies (Func)

Clone

1H10
  • Fonction

    anti-PD-1 (mouse), mAb (blocking) (1H10)

    Attributs du produit

    Monoclonal Antibody. Recognizes mouse PD-1 (CD279). Does not cross-react with human PD-1d. Isotype: Rat IgG2akappa. Clone: 1H10. Applications: FACS, FUNC (Blocking). Liquid. In PBS containing 0.02 % sodium azide. CD279 (Programmed Cell Death Protein 1, PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses. Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or downregulate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, myeloid cells and on a subset of thymocytes. In vitro, ligation of CD279 inhibits TCR-mediated T cell proliferation and production of IL-1, IL-4, IL-10 and IFN-gamma. In addition, CD279 ligation also inhibits BCR mediated signaling. CD279 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases.

    Pureté

    >95 % (SDS-PAGE)

    niveau d'endotoxine

    <0.01EU/μg purified protein (LAL test, Lonza).

    Immunogène

    Mouse PD-1 transfected cell line.

    Isotype

    IgG2a kappa
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    Lot specific

    Buffer

    Liquid. In PBS containing 0.02 % sodium azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Conseil sur la manipulation

    After opening, prepare aliquots and store at -20 °C. Avoid freeze/thaw cycles.

    Stock

    4 °C,-20 °C

    Stockage commentaire

    Short Term Storage: +4°C

    Long Term Storage: -20°C

    Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.

  • Antigène

    PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

    Autre désignation

    PD-1

    Sujet

    Alternate Names/Synonyms: CD279, Programmed Cell Death Protein 1

    Product Description: CD279 (Programmed Cell Death Protein 1, PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses. Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or downregulate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, myeloid cells and on a subset of thymocytes. In vitro, ligation of CD279 inhibits TCR-mediated T cell proliferation and production of IL-1, IL-4, IL-10 and IFN-gamma. In addition, CD279 ligation also inhibits BCR mediated signaling. CD279 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases.

    NCBI Accession

    NP_005009

    Pathways

    Cancer Immune Checkpoints
Vous êtes ici:
Chat with us!